Clinical Trial Update: VERIFY: Vedolizumab for the Prevention of Immune Checkpoint Inhibitor Related Diarrhea or Colitis in Patients With Cancer [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trial investigating vedolizumab to prevent immune checkpoint inhibitor-related diarrhea or colitis in cancer patients. Status: not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• Vedolizumab (vedolizumab)

Snippet

Sponsor: University of Calgary | Conditions: Cancer, Cancer Metastatic | Phase 2, Phase 3 | Status: NOT_YET_RECRUITING